Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257
Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002
EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.
Moschini, 2016, Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy, Eur Urol, 69, 193, 10.1016/j.eururo.2015.07.047
James, 2016, Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial, JAMA Oncol, 2, 348, 10.1001/jamaoncol.2015.4350
Seisen, 2018, Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis, Eur Urol, 73, 452, 10.1016/j.eururo.2017.08.011
Ventimiglia, 2019, A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer, Eur Urol Oncol, 2, 294, 10.1016/j.euo.2019.02.001
Hofman, 2018, A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol, BJU Int, 122, 783, 10.1111/bju.14374
Pilepich, 2005, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31, Int J Radiat Oncol Biol Phys, 61, 1285, 10.1016/j.ijrobp.2004.08.047
Warde, 2011, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, Lancet, 378, 2104, 10.1016/S0140-6736(11)61095-7
Bolla, 2010, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 11, 1066, 10.1016/S1470-2045(10)70223-0
Bolla, 2009, Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, 360, 2516, 10.1056/NEJMoa0810095
James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900
James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5
Abdollah, 2015, More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer, Eur Urol, 67, 212, 10.1016/j.eururo.2014.05.011
Briganti, 2009, Pelvic lymph node dissection in prostate cancer, Eur Urol, 55, 1251, 10.1016/j.eururo.2009.03.012
Touijer, 2014, Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy, Eur Urol, 65, 20, 10.1016/j.eururo.2013.03.053
Touijer, 2018, Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies, Eur Urol, 73, 890, 10.1016/j.eururo.2017.09.027
Gupta, 2019, Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit, BJU Int, 123, 252, 10.1111/bju.14241
Abdollah, 2018, Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection, Eur Urol, 74, 253, 10.1016/j.eururo.2018.04.017
Van den Broeck, 2019, Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review, Eur Urol, 75, 967, 10.1016/j.eururo.2018.10.011
Tilki, 2019, External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort, Eur Urol, 75, 896, 10.1016/j.eururo.2019.03.016
Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029
Parekh, 2013, Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review, Semin Radiat Oncol, 23, 222, 10.1016/j.semradonc.2013.01.006
Crook, 2019, A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology/RTOG-0526), Int J Radiat Oncol Biol Phys, 103, 335, 10.1016/j.ijrobp.2018.09.039
Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002
Pisansky, 2019, Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline amendment 2018–2019, J Urol, 202, 533, 10.1097/JU.0000000000000295
Pompe, 2018, Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence, Prostate, 78, 676, 10.1002/pros.23511
Tilki, 2015, External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort, J Urol, 193, 1970, 10.1016/j.juro.2014.12.020
Shipley, 2017, Radiation with or without antiandrogen therapy in recurrent prostate cancer, N Engl J Med, 376, 417, 10.1056/NEJMoa1607529
Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X
Carrie, 2019, Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial, Lancet Oncol, 20, 1740, 10.1016/S1470-2045(19)30486-3
Pollack, 2018, Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial, Int J Radiat Oncol Biol Phys, 102, 1605, 10.1016/j.ijrobp.2018.08.052
Spratt, 2018, A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer, Eur Urol, 73, 156, 10.1016/j.eururo.2017.06.027
Preisser, 2019, Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes, Eur Urol, 76, 106, 10.1016/j.eururo.2019.01.048
Wiegel, 2015, Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial, Int J Radiat Oncol Biol Phys, 91, 288, 10.1016/j.ijrobp.2014.09.039
Ploussard, 2013, Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy, J Urol, 190, 1750, 10.1016/j.juro.2013.04.073
Fossati, 2018, Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy, Eur Urol, 73, 436, 10.1016/j.eururo.2017.07.026
Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8
Loblaw, 2018, Timing of androgen deprivation therapy for prostate cancer patients after radiation: planned combined analysis of two randomized phase 3 trials, Int J Radiat Oncol Biol Phys, 102, S148, 10.1016/j.ijrobp.2018.06.358
Hofman, 2018, Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls, Radiographics, 38, 200, 10.1148/rg.2018170108
Paschalis, 2019, Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer, Eur Urol, 76, 469, 10.1016/j.eururo.2019.06.030
Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N. Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. In press. https://doi.org/10.1111/bju.14814.
Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3
Burdett, 2019, Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis, Eur Urol, 76, 115, 10.1016/j.eururo.2019.02.003
Khoo, 2019, New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly, Clin Radiol, 74, 865, 10.1016/j.crad.2019.05.003
Kothari, 2019, Trends in management of oligometastatic hormone-sensitive prostate cancer, Curr Oncol Rep, 21, 43, 10.1007/s11912-019-0791-5
Lancia, 2019, Oligometastatic prostate cancer: the game is afoot, Cancer Treat Rev, 73, 84, 10.1016/j.ctrv.2019.01.005
D’Angelillo, 2019, Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO), Crit Rev Oncol Hematol, 138, 24, 10.1016/j.critrevonc.2019.03.014
Patel, 2019, Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer, World J Urol, 37, 2615, 10.1007/s00345-019-02873-w
Perez-Lopez, 2019, Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art, Radiology, 292, 273, 10.1148/radiol.2019181931
Crawford, 2019, A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III), J Urol, 201, 682, 10.1016/j.juro.2018.05.164
Fanti, 2018, Consensus on molecular imaging and theranostics in prostate cancer, Lancet Oncol, 19, e696, 10.1016/S1470-2045(18)30604-1
Hofman, 2018, Advances in urologic imaging: prostate-specific membrane antigen ligand PET imaging, Urol Clin North Am, 45, 503, 10.1016/j.ucl.2018.03.016
Vapiwala, 2019, Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart, J Clin Oncol, 37, 765, 10.1200/JCO.18.01927
Ost, 2017, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853
Siva, 2018, Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004
Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5
Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001
Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645
Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657
Foster, 2019, Oligometastatic prostate cancer: reality or figment of imagination?, Cancer, 125, 340, 10.1002/cncr.31860
Pezaro, 2017, Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from’ castration-resistant’ prostate cancer, Ann Oncol, 28, 1692, 10.1093/annonc/mdx312
Armstrong, 2018, Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet, Ann Oncol, 29, 23, 10.1093/annonc/mdx648
Agrawal, 2016, Prevalence of hypogonadism in low-risk prostate cancer survivors, Fed Pract, 33, 37s
Klotz, 2015, Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT, J Clin Oncol, 33, 1151, 10.1200/JCO.2014.58.2973
Cao, 2017, Accuracy-based proficiency testing for testosterone measurements with immunoassays and liquid chromatography-mass spectrometry, Clin Chim Acta, 469, 31, 10.1016/j.cca.2017.03.010
Rosner, 2007, Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement, J Clin Endocrinol Metab, 92, 405, 10.1210/jc.2006-1864
Rosner, 2010, Toward excellence in testosterone testing: a consensus statement, J Clin Endocrinol Metab, 95, 4542, 10.1210/jc.2010-1314
van der Sluis, 2012, Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry, J Urol, 187, 1601, 10.1016/j.juro.2011.12.063
Vesper, 2010, Standardization of testosterone measurements in humans, J Steroid Biochem Mol Biol, 121, 513, 10.1016/j.jsbmb.2010.03.032
Kunath, 2015, Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer: a systematic review with meta-analysis, BMJ Open, 5, 10.1136/bmjopen-2015-008217
Van Poppel, 2008, Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker—results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer, Eur Urol, 54, 805, 10.1016/j.eururo.2008.04.065
2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2
James, 2015, Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032
Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747
Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0
Tucci, 2016, Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis, Eur Urol, 69, 563, 10.1016/j.eururo.2015.09.013
Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1
Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307
Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835
Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174
Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799
Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396
Hoyle, 2019, Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer, Eur Urol, 76, 719, 10.1016/j.eururo.2019.08.006
Sydes, 2018, Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol, Ann Oncol, 29, 1235, 10.1093/annonc/mdy072
Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Cancer Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309
Watson, 2015, Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer, Nat Rev Cancer, 15, 701, 10.1038/nrc4016
de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618
Ryan, 2012, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096
Attard G, Merseburger AS, Arlt W, et al. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate: a randomized, open-label phase 2 study. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2019.1011.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer version 4.2019—August 19, 2019.
Smith, 2018, ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC), J Clin Oncol, 36, 10.1200/JCO.2018.36.6_suppl.TPS383
Bryce, 2017, Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL, Prostate Cancer Prostatic Dis, 20, 221, 10.1038/pcan.2016.71
Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702
Fizazi, 2019, Darolutamide in nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 380, 1235, 10.1056/NEJMoa1815671
Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536
Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546
Fendler, 2019, Prostate-specific membrane antigen ligand positron-emission tomography in men with nonmetastatic castration-resistant prostate cancer, Clin Cancer Res, 25, 7448, 10.1158/1078-0432.CCR-19-1050
Smith, 2005, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, J Clin Oncol, 23, 2918, 10.1200/JCO.2005.01.529
Tombal, 2019, Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 556, 10.1016/S1470-2045(18)30898-2
Saad, 2018, Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1404, 10.1016/S1470-2045(18)30456-X
Ryan, 2018, The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer, J Urol, 200, 344, 10.1016/j.juro.2018.03.125
Attard, 2018, Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment, J Clin Oncol, 36, 2639, 10.1200/JCO.2018.77.9827
de Bono, 2018, Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe, Eur Urol, 74, 37, 10.1016/j.eururo.2017.07.035
Morris, 2019, Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC), J Clin Oncol, 37, 5008, 10.1200/JCO.2019.37.15_suppl.5008
de Wit, 2019, Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer, N Engl J Med, 381, 2506, 10.1056/NEJMoa1911206
Hussain, 2019, PROfound: phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations, Ann Oncol, 30, 10.1093/annonc/mdz394.039
Khalaf, 2019, Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial, Lancet Oncol, 20, 1730, 10.1016/S1470-2045(19)30688-6
Armstrong, 2019, Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study, J Clin Oncol, 37, 1120, 10.1200/JCO.18.01731
Sumanasuriya, 2018, Consensus statement on circulating biomarkers for advanced prostate cancer, Eur Urol Oncol, 1, 151, 10.1016/j.euo.2018.02.009
Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815
Scher, 2016, Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer, JAMA Oncol, 2, 1441, 10.1001/jamaoncol.2016.1828
Sharp, 2019, Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer, J Clin Invest, 129, 192, 10.1172/JCI122819
Sharp, 2019, Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer, Eur Urol, 76, 676, 10.1016/j.eururo.2019.04.006
Szmulewitz, 2018, Prospective International Randomized Phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer, J Clin Oncol, 36, 1389, 10.1200/JCO.2017.76.4381
Shore, 2016, Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study, Lancet Oncol, 17, 153, 10.1016/S1470-2045(15)00518-5
von Eyben, 2018, Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178–211, Eur Urol, 73, e31, 10.1016/j.eururo.2017.08.010
Hofman, 2018, [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study, Lancet Oncol, 19, 825, 10.1016/S1470-2045(18)30198-0
Violet J, Sandhu S, Iravani A, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med. In press. https://doi.org/10.2967/jnumed.119.236414.
Sartor, 2019, VISION: an international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 37, 10.1200/JCO.2019.37.15_suppl.TPS5099
Hofman, 2019, TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603), BJU Int, 124, 5, 10.1111/bju.14876
Thang, 2019, Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for (177)Lu-labelled PSMA radioligand therapy, Eur Urol Oncol, 2, 670, 10.1016/j.euo.2018.11.007
Mannweiler, 2009, Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis, Pathol Oncol Res, 15, 167, 10.1007/s12253-008-9104-2
Aggarwal, 2018, Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer, Eur Urol Oncol, 1, 78, 10.1016/j.euo.2018.03.010
Dorff, 2019, The evolving role of prostate-specific membrane antigen–based diagnostics and therapeutics in prostate cancer, Am Soc Clin Oncol Educ Book, 39, 321, 10.1200/EDBK_239187
Smith, 2019, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 408, 10.1016/S1470-2045(18)30860-X
Gralow, 2013, NCCN task force report: bone health in cancer care, J Natl Compr Canc Netw, 11, S1, 10.6004/jnccn.2013.0215
Coleman, 2014, Bone health in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 25
Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458
Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141
Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6
Pezaro, 2014, Visceral disease in castration-resistant prostate cancer, Eur Urol, 65, 270, 10.1016/j.eururo.2013.10.055
Tombal, 2019, Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis, J Clin Oncol, 37, 5007, 10.1200/JCO.2019.37.15_suppl.5007
NICE, 2019, NICE guidance—prostate cancer: diagnosis and management. (c) NICE (2019) Prostate cancer: diagnosis and management, BJU Int, 124, 9, 10.1111/bju.14809
Ku, 2019, Towards precision oncology in advanced prostate cancer, Nat Rev Urol, 16, 645, 10.1038/s41585-019-0237-8
Abida, 2019, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade, JAMA Oncol, 5, 471, 10.1001/jamaoncol.2018.5801
Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596
Antonarakis, 2019, Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: updated analysis of KEYNOTE-199, J Clin Oncol, 37, 216, 10.1200/JCO.2019.37.7_suppl.216
Tucker, 2019, Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer, Cancer Med, 8, 4644, 10.1002/cam4.2375
Nava Rodrigues, 2018, Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, J Clin Invest, 128, 4441, 10.1172/JCI121924
Marshall, 2019, CDK12 inactivation across solid tumors: an actionable genetic subtype, Oncoscience, 6, 312, 10.18632/oncoscience.481
Wu, 2018, Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer, Cell, 173, 10.1016/j.cell.2018.04.034
Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859
Chung, 2019, Prospective comprehensive genomic profiling of primary and metastatic prostate tumors, JCO Precis Oncol., 3
Schweizer, 2019, Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations, JCO Precis Oncol, 3
Abida, 2017, Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making, JCO Precis Oncol., 2017
Clarke, 2018, Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, 19, 975, 10.1016/S1470-2045(18)30365-6
Mateo, 2019, TOPARP-B: a phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations, J Clin Oncol, 37, 5005, 10.1200/JCO.2019.37.15_suppl.5005
Abida, 2018, 793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations, Ann Oncol, 29, 10.1093/annonc/mdy284.002
Hager, 2016, Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review, Ann Oncol, 27, 975, 10.1093/annonc/mdw156
Leal, 2019, Effectiveness of platinum-based chemotherapy in patients with metastatic prostate cancer: systematic review and meta-analysis, Clin Genitourin Cancer, 17, e627, 10.1016/j.clgc.2019.03.008
Pomerantz, 2017, The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer, Cancer, 123, 3532, 10.1002/cncr.30808
Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022
Zafeiriou, 2019, Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency, Eur Urol, 75, 184, 10.1016/j.eururo.2018.09.048
Christenson, 2018, PARP inhibitors for homologous recombination-deficient prostate cancer, Expert Opin Emerg Drugs, 23, 123, 10.1080/14728214.2018.1459563
Choi, 2016, Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer, Cell Rep, 14, 429, 10.1016/j.celrep.2015.12.046
Horak P, Weischenfeldt J, von Amsberg G, et al. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. In press. https://doi.org/10.1101/mcs.a003657.
Lombard, 2019, Overexpressed ABCB1 induces olaparib-taxane cross-resistance in advanced prostate cancer, Transl Oncol, 12, 871, 10.1016/j.tranon.2019.04.007
Lord, 2013, Mechanisms of resistance to therapies targeting BRCA-mutant cancers, Nat Med, 19, 1381, 10.1038/nm.3369
Quigley, 2017, Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors, Cancer Discov, 7, 999, 10.1158/2159-8290.CD-17-0146
Franzese, 2019, PARP inhibitors in ovarian cancer, Cancer Treat Rev, 73, 1, 10.1016/j.ctrv.2018.12.002
Taylor, 2019, The influence of BRCA2 mutation on localized prostate cancer, Nat Rev Urol, 16, 281, 10.1038/s41585-019-0164-8
Montironi, 2018, Features and prognostic significance of intraductal carcinoma of the prostate, Eur Urol Oncol, 1, 21, 10.1016/j.euo.2018.03.013
Giri, 2018, Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017, J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173
Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144
Nicolosi, 2019, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines, JAMA Oncol, 5, 523, 10.1001/jamaoncol.2018.6760
Yadav, 2018, Intratumor heterogeneity in prostate cancer, Urol Oncol, 36, 349, 10.1016/j.urolonc.2018.05.008
Wei, 2017, Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators, Eur Urol, 71, 183, 10.1016/j.eururo.2016.07.008
Shoag, 2016, Clinical variability and molecular heterogeneity in prostate cancer, Asian J Androl, 18, 543, 10.4103/1008-682X.178852
Ang, 2017, Outcomes of dose-attenuated docetaxel in Asian patients with castrate-resistant prostate cancer, Ann Acad Med Singapore, 46, 195, 10.47102/annals-acadmedsg.V46N5p195
Kita, 2013, Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients, Int J Clin Oncol, 18, 718, 10.1007/s10147-012-0443-3
Zhou, 2015, A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer, PLoS One, 10
Poon, 2018, Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naive prostate cancer: The first real-life experience in Asia, Asia Pac J Clin Oncol, 14, 347, 10.1111/ajco.12874
Poon, 2015, Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer, Prostate Int, 3, 51, 10.1016/j.prnil.2015.03.002
Chiong, 2019, Management of patients with advanced prostate cancer in the Asia Pacific region:’ real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017, BJU Int, 123, 22, 10.1111/bju.14489
Renehan, 2016, How to manage the obese patient with cancer, J Clin Oncol, 34, 4284, 10.1200/JCO.2016.69.1899
Allott, 2013, Obesity and prostate cancer: weighing the evidence, Eur Urol, 63, 800, 10.1016/j.eururo.2012.11.013
Droz, 2017, Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology, Eur Urol, 72, 521, 10.1016/j.eururo.2016.12.025
Kessler, 2018, Management of metastatic prostate cancer in frail/elderly patients, Oncology, 32, 570
Kalsi, 2015, The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people, Br J Cancer, 112, 1435, 10.1038/bjc.2015.120
Graff, 2016, Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL, Ann Oncol, 27, 286, 10.1093/annonc/mdv542
Siemens, 2018, Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial, J Urol, 199, 147, 10.1016/j.juro.2017.08.080
Smith, 2015, Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer, J Urol, 194, 1277, 10.1016/j.juro.2015.07.004
Costa, 2019, Hematologic toxicity of radium-223 in elderly patients with metastatic castration resistant prostate cancer: a real-life experience, Prostate Int, 7, 25, 10.1016/j.prnil.2018.08.001
Wong, 2015, Docetaxel in very elderly men with metastatic castration-resistant prostate cancer, Prostate Int, 3, 42, 10.1016/j.prnil.2015.03.003
Italiano, 2009, Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer, Eur Urol, 55, 1368, 10.1016/j.eururo.2008.07.078
Heidenreich, 2014, Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme, Eur J Cancer, 50, 1090, 10.1016/j.ejca.2014.01.006
Rivoirard, 2016, Chemotherapy regimen in nonagenarian cancer patients: a bi-institutional experience, Chemotherapy, 61, 65, 10.1159/000441018
Borno, 2019, All men are created equal: addressing disparities in prostate cancer care, Am Soc Clin Oncol Educ Book, 39, 302, 10.1200/EDBK_238879
Halabi, 2019, Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel, J Clin Oncol, 37, 403, 10.1200/JCO.18.01279
Dess, 2019, Association of black race with prostate cancer-specific and other-cause mortality, JAMA Oncol, 5, 975, 10.1001/jamaoncol.2019.0826
Bernard, 2017, Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer, Cancer, 123, 1536, 10.1002/cncr.30503
Halabi S, Dutta S, Tangen CM, et al. Comparative survival of Asian and white men with metastatic castration-resistant prostate cancer treated with docetaxel. JNCI Cancer Spectr. In press.
Huang, 2017, Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations, Cancer Discov, 7, 973, 10.1158/2159-8290.CD-16-0960
Karakas, 2017, Molecular mechanisms involving prostate cancer racial disparity, Am J Clin Exp Urol, 5, 34
Jaratlerdsiri, 2018, Whole-genome sequencing reveals elevated tumor mutational burden and initiating driver mutations in African men with treatment-naive, high-risk prostate cancer, Cancer Res, 78, 6736, 10.1158/0008-5472.CAN-18-0254
Templeton, 2013, Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials, Ann Oncol, 24, 2972, 10.1093/annonc/mdt397
Walker, 2013, Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects, Clin Genitourin Cancer, 11, 375, 10.1016/j.clgc.2013.05.004
Karling, 1994, Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma, J Urol, 152, 1170, 10.1016/S0022-5347(17)32530-2
Nishiyama, 2004, Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy, Int J Urol, 11, 735, 10.1111/j.1442-2042.2004.00896.x
Freedman, 2005, Hot flashes: behavioral treatments, mechanisms, and relation to sleep, Am J Med, 118, 124, 10.1016/j.amjmed.2005.09.046
Penson, 2003, Health related quality of life in men with prostate cancer, J Urol, 169, 1653, 10.1097/01.ju.0000061964.49961.55
Ulloa, 2009, Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer, Psychooncology, 18, 598, 10.1002/pon.1427
Gonzalez, 2015, Course and moderators of hot flash interference during androgen deprivation therapy for prostate cancer: a matched comparison, J Urol, 194, 690, 10.1016/j.juro.2015.03.026
McCallum, 1989, Hot flushes are induced by thermogenic stimuli, Br J Urol, 64, 507, 10.1111/j.1464-410X.1989.tb05288.x
Irani, 2010, Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial, Lancet Oncol, 11, 147, 10.1016/S1470-2045(09)70338-9
Sella, 1998, Antiandrogen withdrawal syndrome with cyproterone acetate, Urology, 52, 1091, 10.1016/S0090-4295(98)00354-9
Wehbe, 1997, Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer, Mayo Clin Proc, 72, 932, 10.1016/S0025-6196(11)63364-8
Beer, 2010, Acupuncture for hot flashes in patients with prostate cancer, Urology, 76, 1182, 10.1016/j.urology.2010.03.033
Lee, 2009, Acupuncture for treating hot flushes in men with prostate cancer: a systematic review, Support Care Cancer, 17, 763, 10.1007/s00520-009-0589-3
Nelson, 2016, Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison, Support Care Cancer, 24, 4159, 10.1007/s00520-016-3241-z
Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095
Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506
Hussain, 2016, Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details, J Clin Oncol, 34, 280, 10.1200/JCO.2015.62.8065
Hussain, 2013, Intermittent versus continuous androgen deprivation in prostate cancer, N Engl J Med, 368, 1314, 10.1056/NEJMoa1212299
Segal, 2003, Resistance exercise in men receiving androgen deprivation therapy for prostate cancer, J Clin Oncol, 21, 1653, 10.1200/JCO.2003.09.534
Taaffe, 2017, Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial, Eur Urol, 72, 293, 10.1016/j.eururo.2017.02.019
Galvao, 2018, Exercise preserves physical function in prostate cancer patients with bone metastases, Med Sci Sports Exerc, 50, 393, 10.1249/MSS.0000000000001454
Thiery-Vuillemin, 2018, Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study, ESMO Open, 3, 10.1136/esmoopen-2018-000397
Parimi, 2016, Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 34, 5059, 10.1200/JCO.2016.34.15_suppl.5059
Pilon, 2017, Assessment of Real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy, Am Health Drug Benefits, 10, 143